Oura Agrees to Acquire Counsel Health for $625 Million in Cash

Oura has entered into a definitive agreement to acquire Counsel Health, the AI-native primary care company, for $625 million in cash, subject to purchase price adjustments, according to a Counsel Health newsroom announcement. The deal brings together Oura's wearable-driven health data platform with Counsel's physician-supervised care model, extending a partnership between the two companies that began in May 2026, as described in Oura's own blog post on the agreement.

Deal Terms

The acquisition is structured entirely as a cash transaction. Oura's executive chairman, David Shuman, tied the deal to the company's financial position, stating that "Oura's record growth of 153 percent this quarter and our over six million members provides us the confidence to invest $625 million cash to acquire Counsel Health," per the Counsel Health announcement. No stock component, earnout structure, or other consideration details were disclosed in the available materials, and the final price remains subject to purchase price adjustments that were not itemized.

What Counsel Health Brings

Counsel Health is described in the announcement as an AI-native primary care company serving health plans, health systems, digital health solutions, employers, and consumers. Oura has stated that following the acquisition, Counsel will continue to serve its existing and new enterprise partners, including health plans and health systems, with the stated goal of bringing its care model to millions of patients beyond Oura's member base, including people who do not wear an Oura Ring. Read together, these statements indicate — as an interpretation of the companies' stated plans rather than a confirmed outcome — that Counsel's existing health-plan and health-system relationships are intended to continue operating alongside, and not be limited to, Oura's ring-wearing membership.

Shuman framed the enterprise relationships as a strategic rationale for the deal, saying the combination "expands our addressable market and deepens the value we deliver to every member," and adding that it "not only increases lifetime value, but Counsel's enterprise partners also open the door to millions of people beyond our existing member base." These are company statements about strategic intent rather than independently confirmed outcomes.

Why Oura Says It's Doing This Now

Oura CEO Tom Hale pointed to broader pressures on the U.S. primary care system as a motivating factor, saying that "getting care is increasingly difficult due to a confluence of higher healthcare costs, a shortage of doctors, and limited time allotted to live doctor-patient visits," and that Oura and Counsel together can help bridge that gap, according to Oura's blog post. The same post cited figures indicating that a typical primary care visit in the U.S. lasts about 18 minutes and that the country could face a shortage of as many as 86,000 physicians by 2036, though the post did not identify the original source of those statistics.

Counsel Health founder and CEO Dr. Muthu Alagappan said that "continuous health context makes medical AI more useful and relevant to each person," adding that "at Counsel, we've built medical AI with a focus on trust, safety, and responsibility, keeping physicians in the loop for clinical decision-making," according to Oura's blog post.

The companies pointed to early engagement figures from the existing partnership rather than financial projections. Oura's post said that since the partnership began, more than half of Counsel users in Oura Labs have shared their Oura data with their physicians. The Counsel Health announcement said that among members using Counsel, more than 90 percent of those surveyed said their Oura data helped them get better care, and that members who saw a Counsel physician rated their care experience 4.6 out of 5. These are company-reported survey and usage metrics, and the announcements did not disclose sample sizes or survey methodology. The two companies also said they plan to build on the existing partnership across three areas of care: preventive care, acute care, and specialty and chronic care.

Bottom line: Oura has agreed to pay $625 million in cash, subject to purchase price adjustments, for a primary care company it has partnered with since May 2026. No stock component, earnout, revenue contribution, or closing timeline was disclosed in the available announcements, and the companies' statements about expanded addressable market and member lifetime value are expressions of strategic intent that have not been quantified or independently verified.